Keyphrases
Psoriatic Arthritis
100%
Skin Psoriasis
100%
Infliximab
44%
Etanercept
44%
Tumor Necrosis Factor-α
33%
Rheumatoid Arthritis
22%
Monoclonal Antibody
11%
Quality of Life
11%
Inflammatory Response
11%
Randomized Placebo-controlled Trial
11%
Cell Surface
11%
New Therapeutics
11%
Therapeutic Potential
11%
Psoriatic
11%
Symptomatology
11%
Disease Course
11%
TNF Receptor 1 (TNFR1)
11%
Life Impairments
11%
Controlled Experiment
11%
Rationally Designed
11%
US Population
11%
Fusion Protein
11%
Significant Benefit
11%
Anecdotal Evidence
11%
Joint Damage
11%
Arthropathy
11%
Tumour Necrosis Factor Inhibitor (TNFi)
11%
Joint Quality
11%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Psoriatic Arthritis
100%
Infliximab
44%
Etanercept
44%
Tumor Necrosis Factor
33%
Rheumatoid Arthritis
22%
Inflammatory Arthritis
22%
Inflammation
11%
Placebo
11%
Receptor
11%
Disease Course
11%
Tumor Necrosis Factor Receptor
11%
Controlled Clinical Trial
11%
Human Monoclonal Antibody
11%
Arthropathy
11%
Tumor Necrosis Factor Inhibitor
11%
Symptomatology
11%
Chimeric Protein
11%
Immunology and Microbiology
Psoriatic Arthritis
100%
Infliximab
44%
Etanercept
44%
Tumor Necrosis Factor
33%
Inflammatory Arthritis
22%
Human Monoclonal Antibody
11%
Inflammation Response
11%
Cell Surface
11%
Tumor Necrosis Factor Receptor
11%
Arthropathy
11%
TNF Inhibitor
11%